LOF mutations of STAG2 are significantly elevated in metastatic breast cancer tumors when compared with lower grades (Repo et al., 2016), suggesting that STAG2 has a role in preventing tumor transition to malignancy. This evidence concerns the gene STAG2 and neoplasm.